CTLA4 and lymphedema: In order to dissect the effect of immunotherapy on lymphedema risk, we analyzed within the LAD group if immunotherapy either as monotherapy or in combination (anti-CTLA4, anti-PD1 or interferon) influences lymphedema risk.